RobustoMed

RobustoMed, division of Enzolytics

[Enzoimmune Active @enzoimmune]

In response to your numerous inquiries: yes, we confirm again that we are ready to start sales in Africa of the Enzolytics product - ITV-1 in year 2022. No FDA or EMA registration will be required for that market.

[RobustoMed @RobustoMed]

Great article on Insider Financial - this guy gets it.
https://t.co/fxMXmNfPBq

[Gaurav Chandra M.D. @drgauravchandra]

@CryptoGodDude @enzolytics Leveraging quantum computing in computer-aided drug discovery will significantly improve the steps in drug discovery in the future. Though it is too early for this to make an impact, we have been looking at Monoclonal Antibodies, and binding sites in 3-Dimensional space. #AI

[RobustoMed @RobustoMed]

More than one product - a platform + many products. Proud to be a part of this inspirational effort.

[Gaurav Chandra M.D. @drgauravchandra]

1. We have made great progress and now have multiple platforms for providing multiple therapeutics for the treatment of many diseases. These platforms will cover an extensive range of diseases. #enzc #revenue #hiv #sarscov2 #uplist https://t.co/tmTj6ChB1K

[RobustoMed @RobustoMed]

Lucky to have Gaurav as a part of ENZC.

[Gaurav Chandra M.D. @drgauravchandra]

AI is a significant driver for advancing healthcare, and understanding the Human Microbiome will be pivotal to that transformation. Unlocking the potential of the Human Microbiome utilizing Artificial Intelligence. @YuanCommunity #ENZC #AI #MICROBIOME https://t.co/GnMnAzHlhQ

[Gaurav Chandra M.D. @drgauravchandra]

Enzolytics move forward rapidly with a strategic focus on revenues as we introduce Enzolytics IPF Immune to the North American market.
#ENZC #REVENUE #immunemodulator

https://t.co/vNiypDAXAZ

[Gaurav Chandra M.D. @drgauravchandra]

@Demi6851 “It doesn’t matter how slowly you go as long as you do not stop.”  -Confucious.#ENZC continues to March towards success from one milestone to another. We have come a long way and lots of opportunities coming #Covid_19 #HIv #Itv1 @enzolytics #enzcstrong
#immunemodulator #revenue

[RobustoMed @RobustoMed]

OTC filing on ENZC today. Includes funding for RobustoMed. https://t.co/SNdZZ4aTeZ

[Gaurav Chandra M.D. @drgauravchandra]

Let no feeling of discouragement prey upon you, and in the end, you are sure to succeed-Abraham Lincoln. Lots to achieve in 2021 as we march forward, fulfilling our milestones. #ENZC #ENZCstrong #animalmabs #immunemodulator #uplist #HIV #COVID #sciencewillwin

[Gaurav Chandra M.D. @drgauravchandra]

We take rapid strides in the development of Monoclonal Antibodies for Veterinary use. Phage Display technology to accelerate the antibody discovery process and create novel molecules that can lead to breakthroughs in technology and medicine. #ENZC #AI
https://t.co/VidtigaCVQ

[RobustoMed @RobustoMed]

...

[Gaurav Chandra M.D. @drgauravchandra]

@Ehdgroup We have created Universal, Durable, Broadly Neutralizing Monoclonal Antibodies. 2 Million isolates were analyzed and confirmed that target sites were conserved in ALL #VOC and #VOI . #Delta, #Lambda, #Alpha, #Beta, & #Gamma. Our #MonoclonalAntibodies prevent "virus escape" #AI

[RobustoMed @RobustoMed]

https://t.co/DqRymKRzwv

[RobustoMed @RobustoMed]

Happy ( and proud!) to respond. RobustoMed is a wholly owned subsidiary of ENZC. https://t.co/C6n0KCgxaY

[Right @right_history82]

@drgauravchandra could you breakdown the relationship @enzolytics has with @robustomed,inc

[Gaurav Chandra M.D. @drgauravchandra]

#ENZC It is our time to shine.Onwards and upwards.

[Gaurav Chandra M.D. @drgauravchandra]

Enzolytics Inc. announces the appointment of Steve Sharabura as President of the Company's wholly owned subsidiary RobustoMed, Inc. that will focus on revenue and partnership expansion in Brazil and Costa Rica.
#ENZC #ITV1 https://t.co/7DAPfprQxb via @Yahoo